FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
February 05, 2024 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM...
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
January 16, 2024 17:01 ET | Adagene Inc.
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...
Graphic 1
Goliath Discovers Extensive Mineralization in Multiple Outcrops Over 500 Meters on the Icefields That Remains Wide Open - Golden Triangle, B.C.
August 28, 2023 07:08 ET | Goliath Resources Limited
2023 Icefields Exploration Highlights: Three (3) new zones consisting of sulphide-rich breccia, stockwork and veins in shear zones have been discovered on the icefields claim blocks of the Golddigger...
Infographic 1
CORRECTION -- Goliath Commences Drilling at New Gold-Copper Porphyry and High-Grade Gold Breccia Targets at Its Lucky Strike Property Near Terrace, British Columbia
August 21, 2023 08:48 ET | Goliath Resources Limited
TORONTO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (Frankfurt: B4IF), please note that a...
Infographic 1
Goliath Commences Drilling at New Gold-Copper Porphyry and High-Grade Gold Breccia Targets at Its Lucky Strike Property Near Terrace, British Columbia
August 21, 2023 07:08 ET | Goliath Resources Limited
BULLSEYE GOLD-COPPER PORPHYRY – ~1,000 Metres Diamond Drilling, Highlights: The Bullseye porphyry is a drill ready target that shows all the right components for an extensive gold-copper porphyry...
Infographic 1
Goliath Intercepts 23 Meters* of 21.08 g/t AuEq, Including 14 Meters* of 33.75 g/t AuEq at Surebet Golden Gate Feeder Zone, Golden Triangle, B.C
August 15, 2023 10:18 ET | Goliath Resources Limited
Drill Highlights: GD-23-157 is a 485 gram x meter AuEq hole (15.59 troy ounces gram meter AuEq) collared from Cliff Pad within the Golden Gate Feeder Zone that intercepted Visible Gold mineralization...
Infographic 1
Second Visible Gold Hole Drilled From Cliff Pad at Goliath's Surebet Golden Gate Feeder Zone and 19.87 Meters* of Significant Mineralization, Golden Triangle, B.C.
July 24, 2023 07:00 ET | Goliath Resources Limited
Drill Hole GD-23-135 Highlights: Visible Gold has been intercepted at 60.91 meters within the Surebet Golden Gate Feeder Zone and is the second hole drilled from Cliff Pad in 2023 to contain...
AON Leaders at ASCO 2023
American Oncology Network Announces List of Research Studies Presented at the ASCO 2023 Annual Meeting
June 06, 2023 12:42 ET | American Oncology Network
FORT MYERS, Fla., June 06, 2023 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) announced that six research papers, co-authored by AON physicians and the vice president of pharmacy...
Coherus-Final OS Toripalimab Figure 2 ASCO 2023
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
June 05, 2023 17:30 ET | Coherus BioSciences, Inc.
– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in...
PDS Biotech Logo.png
PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
June 05, 2023 14:52 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...